Aptevo Therapeutics Inc.
APVOHealthcareNASDAQBiotechnology · Last scanned Sep 7, 2026
Scan Results
Daily timeframePart of the healthcare sector, Aptevo Therapeutics Inc. (APVO) is listed under Biotechnology. The company carries a $3.1M market cap, placing it firmly in the micro-cap category. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
Market Cap
$3.1M
Beta
1.61
P/E (TTM)
0.00
P/E (Fwd)
-0.17
EPS (TTM)
$456.62
EPS (Fwd)
$-10.40
ROE
-420.3%
ROA
-111.5%
Cash
$9.8M
Total Debt
$4.2M
Free CF
-$15.6M
52W Change
-93.5%
Annual Financials
Cash vs Debt
Where APVO stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, APVO finished 46.06% below its 150-day moving average ($4.82) and 66.01% below its 200-day moving average ($7.65). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is APVO overbought or oversold?
At the September 3, 2026 close, APVO's RSI(14) was 28.1, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $9.8M in cash and $4.2M in debt, APVO maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$15.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -420.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $3.1M (2022) to $0 (2025), a 100% decline worth watching.
A beta of 1.61 means APVO is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. With cash comfortably exceeding debt, APVO has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Aptevo Therapeutics Inc.'s trajectory.